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ACR Acute Cellular Rejection 
AMR Antibody-Mediated Rejection 
CHD Congenital Heart Disease 
C1q+ C1q Positive 
DSA Donor-Specific Antibody 
EMB Endomyocardial Biopsy 
CAV Cardiac Allograft Vasculopathy 
cPRA Calculated Panel Reactive Antibody 
HLA Human Leukocyte Antigen 
HT Heart Transplant 
min-max Minimum-Maximum 
Q1-Q3 Quartile 1- Quartile 3 
IgG Immunoglobulin G 
IgG+ Immunoglobulin G Positive 
ISHLT International Society for Heart & Lung Transplantation 
IVIG Intravenous Immunoglobulin 
LPCH Lucile Packard Children’s Hospital, Stanford 
MFI Mean Fluorescence Intensity 
pAMR Pathological Antibody-Mediated Rejection 
pAMR1i Pathological Antibody-Mediated Rejection Grade 1 (Immunohistochemistry) 
pAMR2 Pathological Antibody-Mediated Rejection Grade 2 
PCWP Pulmonary Capillary Wedge Pressure 
POD Post-Operative Day 
RAP Right Atrial Pressure 
VAD Ventricular Assist Device 
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Hollander SA,  Peng DM, Mills M, Berry GJ, Fedrigo M, McElhinney DB, Almond CS, Rosenthal DN 
PATHOLOGICAL ANTIBODY-MEDIATED REJECTION IN PEDIATRIC HEART TRANSPLANT RECIPIENTS: 





Biopsy-diagnosed (pathological) antibody-mediated rejection (pAMR) has been observed in over half of 
pediatric heart transplant (HT) recipients within 6 years of transplantation. We report the incidence and 
outcomes of pAMR at our center. All endomyocardial biopsies for all HT recipients transplanted 
between 2010-2015 were reviewed and classified using contemporary ISHLT guidelines. Graft 
dysfunction was defined as a qualitative decrement in systolic function by echocardiogram or an 
increase of ≥3 mmHg in atrial filling pressure by direct measurement. Among 96 patients, pAMR2 
occurred in 7 (7%) over a median follow-up period of 3.1 years, while no cases of pAMR3 occurred. A 
history of congenital heart disease, donor specific antibody (DSA) at transplant, and elevated filling 
pressures were associated with pAMR2. 5/6 (83%) of patients developed new C1q+ DSA at the time of 
pAMR diagnosis. There was a trend towards reduced survival, with 43% of patients dying within 2.3 










Although antibody-mediated rejection (AMR) in the cardiac allograft was first described in the late 
1980s, broad acceptance of AMR as a distinct clinicopathological entity evolved more slowly.
1, 2
 Early 
studies defined AMR using various combinations of clinical and pathological features, including the 
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to employ immunomodulatory therapies in the setting of suspected AMR in the absence of biopsy 
findings.
3-5
 To address these inconsistencies, in 2011, the International Society for Heart & Lung 
Transplantation (ISHLT) published a consensus statement standardizing the nomenclature for the 
pathological findings of antibody-mediated rejection (pAMR), allowing for a more uniform description of 
its histological and immunohistochemical features, a descriptive and numeric grading scheme and, as 
with acute cellular rejection (ACR), providing a framework for the diagnosis of AMR independent of 




With a more consistent diagnostic criterion, there is now a growing body of literature in the adult 
population correlating pAMR severity with hemodynamic disturbance as well as patient and graft 
outcomes.
8-10
 In the pediatric population, however, the prevalence, clinical profile, and prognostic 
significance of pAMR, are not as well described.  To date, few studies have examined the incidence and 
outcomes of pAMR in children utilizing the 2011 criteria.  In 2012, Everitt et al. reported that pAMR 
grade 2 or higher occurred in 18% of endomyocardial biopsies and 59% of pediatric heart transplant (HT) 
recipients, with severe (grade 3) pAMR in 1% of biopsies and 12% of patients.
11
 Although the study did 
not uncover an association between pAMR2 and poor outcomes, pAMR3 was associated with a 
significantly lower freedom from cardiovascular related mortality or cardiac allograft vasculopathy (CAV) 
within 5 years of transplant.
11
 More recent studies in updated cohorts report lower rates, with ≥pAMR2 




The development of the current pAMR grading criteria also offers the opportunity to better examine the 
role of human leukocyte antibody (HLA) and pAMR development. In 2016, Ware, et. al demonstrated 
that the presence of DSA had excellent sensitivity and negative predictive value for biopsy-diagnosed 
AMR using the current criteria, although the study did not examine the role of complement fixation on 
pAMR development.
12
 Since 2007, the pediatric heart transplant program at Stanford University has 
used the C1q assay to define the subset of HLA antibodies capable of fixing complement, as we believe 
complement fixing antibodies are more likely to precipitate myocardial injury.
13
 Though C1q+ DSA have 
been associated with biopsy-diagnosed AMR using earlier definitions, the correlation between C1q+ DSA 
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The purpose of this study was to ascertain the incidence of and risk factors for pAMR using the current 
grading criteria in a single-center cohort of pediatric HT recipients, and to correlate pAMR development 
with changes in immunologic risk factors, changes in ventricular function, and patient outcomes. 
 
Materials & Methods 
 
Study Population and Clinical Data Collection 
We performed a retrospective chart review on all patients who underwent HT at Lucile Packard 
Children’s Hospital, Stanford (LPCH) between January 1, 2010 and December 31, 2015 and who received 
at least one endomyocardial biopsy (EMB). The incidence and outcomes for early (≤1 year) or late (>1 
year) pAMR were analyzed from the time of HT to December 31, 2016. Patients undergoing multi-organ 
(heart-liver) transplant were excluded. 
 
Baseline demographics, including age, gender, race, and pre-transplant diagnosis, as well as all post-
transplantation catheterization and EMB data were extracted from the electronic medical record. All 
EMB catheterizations were included, whether they occurred at LPCH or an outside hospital, however, 
biopsy results were only included if they were interpreted by a Stanford University cardiac pathologist. 
All biopsies underwent un-blinded review by an experienced cardiac pathologist at the time of the 
biopsy procedure and verified later by a visiting extramural scholar who was not blinded to the original 





Induction and Maintenance Immunosuppression 
All patients received induction therapy consisting of methylprednisolone (15 mg/kg IV) intraoperatively. 
Until July 30, 2011 Interleukin-2 blockade with daclizumab (1 mg/kg IV) was given either intraoperatively 
or on postoperative day (POD) 2 and then every 2 weeks for a total of 5 doses. After August 1, 2011, 
basiliximab  (10 or 20 mg IV) was used instead of daclizumab on PODs 1 and 5. After July 1, 2012, rabbit 
anti-thymocyte globulin (1.5 mg/kg/IV daily x 5 days) was used instead of basiliximab. Plasmapheresis 
(1.5 volume exchange) followed by intravenous immunoglobulin (IVIG) (2 g/kg) were given per protocol 
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the attending transplant cardiologist. Post-operatively, all patients received maintenance 
immunosuppressive therapy consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), 
mycophenolate mofetil, and methylprednisolone or prednisone, which was tapered over the first post-
transplant year.  Cyclosporine and tacrolimus dosing were modulated to achieve target troughs of 300-
350 or 10-12 g/dl, respectively, for the first 3 post-transplant months, after which doses were adjusted 
downward sequentially to goal troughs of 200-250 g/dl at 12 months post-transplant for cyclosporine or 
6-8 g/dl by 6 months post-transplant for tacrolimus. Select patients were transitioned to sirolimus at 
various time points at least 6 months post-transplant and were dosed to achieve a target trough of 6-8 
g/dl and continued on reduced-dose cyclosporine or tacrolimus adjusted to achieve target troughs of 
100-150 or 2-4 g/dl, respectively. Patients with persistent DSA following cardiac transplantation 
continued to receive monthly IVIG postoperatively at the discretion of the attending transplant 
cardiologist. 
 
DSA Assay and C1q Virtual Crossmatch Avoidance Strategy 




 All patients had a virtual crossmatch (VXM) performed on their most recent calculated 
panel reactive antibody (cPRA) sample at the time of donor offer.  While each donor offer was 
considered individually based on number of antibody present, mean fluorescence intensity (MFI), overall 
organ quality, and clinical status of the patient, from an immunological standpoint, in general, organs 
that caused a C1q+ VXM were typically rejected while organs that were VXM positive by IgG (IgG+) only 
were typically accepted. DSA were then again assayed on the day of transplant (at the time of flow 
cyotometry +/- cytotoxic crossmatching), per routine scheduling (POD #14, POD #28, then monthly until 
6 post-transplant months, then annually), and during episodes of suspected ACR or AMR at the 
discretion of the attending cardiologist.  
 
Rejection Surveillance Protocol 
Immunohistochemical staining (C3d, C4d, CD68) was performed at the discretion of the cardiac 
pathologist or at the request of the transplant cardiologist. Peroxidase staining was not performed. 
Biopsy frequency varied by age, but typically patients would undergo EMB weekly for the first post-HT 
month, biweekly for the 2
nd
 month, monthly until the 6
th
 post-transplant month, and every 3 months 
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thereafter with a small cohort of patients biopsied yearly in the setting of at least moderate tricuspid 





Systolic function was assayed qualitatively (normal, mildly reduced, moderately reduced, severely 
reduced) by echocardiography, which was performed on the same day as EMB. Starting in 2012, routine 
hemodynamic measurements were performed at the time of all endomyocardial biopsies.  Prior to this, 
hemodynamic measurements were recorded during most EMBs at the discretion of the interventional 




The primary outcome studied was the presence or absence of pAMR2 or greater using current ISHLT 
schema.
6
 The total number of EMBs positive for ≥pAMR2 were analyzed as were the total number of 
≥pAMR2 episodes, defined as a positive ≥pAMR2 biopsy subsequent to a normal biopsy (i.e. consecutive 
biopsies positive for ≥pAMR2 were considered as part of a single episode).  Secondary outcomes 
included mean right atrial, pulmonary arterial, and pulmonary capillary wedge pressure (PCWP) 
measurements, change in either left or right atrial filling pressure from prior catheterization defined as 
an increase of ≥3 mmHg in atrial filling pressure by direct measurement, mean PCWP/right atrial 
pressure ratio, and graft dysfunction, defined as a qualitative decrement in systolic function by 
echocardiogram. The presence or absence of DSA at transplant, including the MFI (using the highest 
value if present on multiple beads) of the strongest DSA by both the IgG and C1q methods, were also 
analyzed as risk factors for pAMR development. For DQ antibodies, when alpha typing was reported, 
DSA were identified by both their DQA1* and DQB1* loci and the highest MFI (if present on multiple 
beads) used in the analysis. When DQA1* typing was not available, by convention, DQ antibodies were 
identified by the DQB1* locus only. Changes in IgG and C1q DSA profile were also ascertained at the 
time of pAMR diagnosis. All biopsies were examined for ACR and the histologic features of AMR.  
Immunohistochemical staining was performed at the request of the on-call cardiologist or if if there was 
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prior pAMR positive biopsies were also stained for immunohistochemical findings. For the purposes of 
analysis, no distinction was made between pAMR1 and pAMR0.  
 
Additional outcomes studied were freedom from ≥pAMR2 and overall post-transplant survival in 
patients (dichotimized by those with and those without a history of ≥pAMR2), which were depicted with 
Kaplan-Meier curves. Patients who died without ≥pAMR2 were censored event-free at the time of 
death.  Patients who did not die or have ≥pAMR2 were censored event-free at end of the data collection 
period. Comparison of HT survival between those with and without ≥pAMR2 groups was performed 
using the log-rank test. Univariate Cox regression analysis was used to identify risk factors for the 
development of ≥pAMR2 using all variables with a p value less than 0.1. However, following the 
methodology employed by Everitt et al., comparisons between patients who did and did not develop 
≥pAMR2 were also conducted using Wilcoxon’s rank-sum test or Fisher’s exact test, as appropriate, 
which we felt to be acceptable because the number of events was small and mainly occurred during the 
first HT year, and almost all patients had at least 1 year of follow-up. For continuous data that was 
normally distributed, comparisons between pAMR+ and pAMR- negative patients were conducted using 
unpaired t-tests. Data were presented as median (quartile 1-quartile 3), mean ± standard deviation, or 
count (%). 
 
Data were collected and stored in RedCAP (Version 6.9.7), a web-based application designed to support 
data capture for research studies.
16
 
 Statistics were performed using Microsoft Excel (Version 14.4.8), 
and Stata (Version 12.1, STATA Corp.) was used for time-to-event analysis. This study was approved by 




Baseline demographics and clinical characteristics of those with and without ≥pAMR2 are reported 
in Table 1
 
.  A total of 102 patients were transplanted during the study period.  Three combined heart-
liver transplants were excluded.  Of the remainder, 96 (97%) patients had at least one EMB and were 
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The median age at transplant was 7 (Q1-Q3 1, 15) years. Fifty-four patients (56%) had a pre-transplant 
diagnosis of cardiomyopathy and 40 (42%) had a pre-transplant history of congenital heart disease 
(CHD). Thirty-eight (40%) patients were female.  There were 316 (median 3.1, Q1-Q3 1.9, 4.6) total 
follow-up years.  
 
Incidence of AMR 
During the study period, 1513 EMBs were performed, of which 1055 (70%) were examined for both the 
histological and immunohistochemical features of pAMR and 458 (30%) were examined only 
histologically after the histological features of pAMR were noted to be absent. Thirteen (0.09%) of the 
total number of biopsies, 3% of those that were evaluated both histologically and 
immunohistochemically, were positive for pAMR2. There were 10 discrete pAMR2 episodes in 7 (7%) 
patients, 9 (90%) of which were discovered on routine surveillance biopsies, and one of which was 
associated with grade 3B/3R rejection. Seven (70%) episodes in 6 patients occurred in the first post-
transplant year with a median time to first pAMR2 episode of 16 (Q1-Q3 7,159) days.  Three (30%) 
episodes in 3 patients occurred after the first post-transplant year, 2 (67%) of which were in patients 





No pAMR episodes were associated with systolic dysfunction by echocardiogram. Of 1513 
catheterizations, 1351 (89%) included a right atrial pressure (RAP) measurement, and 1325 (88%) 
included a PCWP measurement. All pAMR2 biopsies included RAP and PCWP pressure measurements, 
and 11/13 (85%) included a mean pulmonary arterial pressure measurement. Only 1 of 10 (10%) pAMR 
episodes was associated with new-onset diastolic dysfunction as defined by an increase of ≥3 mmHg in 
atrial filling pressure by direct measurement. However, mean right atrial (12 ± 6 vs. 7 ± 4, p<0.001), 
pulmonary capillary wedge (16 ± 5 vs. 11 ± 5, p<0.001), and pulmonary arterial (22 ± 3 vs. 18 ± 5, 
p=0.043) pressures were significantly higher when ≥pAMR2 was present than when it was not.  (Table 2
 
) 
These differences remained significant for both the right atrial and pulmonary capillary wedge pressures 
when the 9 ≥pAMR2 biopsies that occurred in the first 3 post-HT months were compared to 
hemodynamics obtained during the same time period when ≥pAMR2 was absent (14 ± 5 mm Hg vs. 8 ± 4 
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Risk Factors for The Development of Early & Late AMR 
Age, sex, and race were not associated with pAMR (p= 0.16-0.79). Forty-one (43%) transplanted patients 
were bridged with a ventricular assist device (VAD), none of whom developed pAMR (p=0.02). pAMR 
was more common in those with a history of CHD (6/7, 86%, p=0.02). In univariate Cox regression 
analysis, both CHD (HR: 9.9, [95% CI = 1.2-83], p=0.034) and absence of VAD (HR: 8.3x10
-17 
 
[95% CI = 0], 
p=0.0036) were significantly associated with ≥pAMR2 development.  
Thirty-one (32%) patients had IgG+ DSA at the time of transplant, including 6 of the 7 (86%) who 
developed pAMR (p=0.004). In the subgroup of those with early pAMR, IgG+ DSA at transplant were 
present in all patients (6/6, 100%), versus 25/65 (38%) who did not (p=0.0001).  Patients with pAMR also 
had an increased median number of IgG+ DSA at transplant (3, Q1-Q3: 2, 5 vs. 0, Q1-Q3: 0,1 p=0.005), 
though the median MFI of the strongest IgG+ DSA was not significantly different between those with 
and without pAMR. (3156, Q1-Q3: 2477, 5429 vs. 2215, Q1-Q3: 1688, 3793, p= 0.09) Seventeen (18%) 
patients had C1q+ DSA discovered at transplant at the time of retrospective crossmatching. This was not 
significantly different between groups (2/7 vs. 15/89 p=0.6). (
 
Table 3) 
At the time of first pAMR diagnosis, data was available for 6 patients, all of whom had IgG+ DSA and 5 of 
whom (83%) had C1q+ DSA.  In 4 cases, C1q+ DSA present at pAMR diagnosis were of different 
specificities than those present by either the IgG or C1q methods at transplant. Two patients had IgG+ 
and C1q+ DSA at pAMR diagnosis that had previously been only IgG+ at transplant. One case of pAMR 
occurred 5 days after transplant in a patient with IgG+/C1q+ DSA at the time of transplant for whom no 
follow-up sample at the time of pAMR diagnosis was obtained.  Details regarding antibody profile at 
transplant and pAMR diagnosis are shown in in Table 4
 
.  
Outcomes Following AMR Diagnosis 
All cases of pAMR resolved. Treatments included IVIG in 6, plasmapheresis and IVIG in 2, and 
bortezomib/rituximab/IVIG/plasmapheresis in 1. One case of late pAMR self-resolved on the first follow-
up biopsy without treatment. During the follow-up period, 3/7 (43%) patients with pAMR died versus 13 
of 89 (15%) without AMR.  The median time from first pAMR episode to death was 369 (min-max 138-
836) days. Although there was no difference in post-transplant survival in those with and without 
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. Of the 3 patients with pAMR2 who died, 1 died of known CAV, 1 had sudden 
cardiac death secondary to presumed CAV, and 1 died of sepsis in the setting of chronic diastolic 
dysfunction and dialysis-dependent renal failure. 
Discussion 
We found that pAMR2 affects 7% of pediatric HT recipients in the first 5 post-transplant years at our 
center. There were no cases of pAMR3 during the same time period. A history of CHD was associated 
with pAMR2 development, but no patient who was bridged to transplantation with VAD developed 
pAMR. The presence of DSA at the time of transplant was associated with early pAMR2. Most patients 
had new C1q+ DSA at the time of pAMR2 diagnosis. Atrial filling pressures were higher when pAMR2 
was present than when it was not, though atrial pressures did not acutely change with pAMR diagnosis. 
Despite biopsy resolution of pAMR2, patients with pAMR2 were at high risk of death within 
approximately 2 years of diagnosis. 
 
The reported prevalence of AMR in children varies, likely due to changes in AMR incidence over time, 
institutional practice including the frequency of routine EMB screening, and differences in the way AMR 
has been previously defined.
4, 9, 11, 12, 17
 Using the Pediatric Heart Transplant Study database, Thrush et al. 
found that 11% of pediatric patients experienced at least one episode of AMR over 5 years. However, 
they used a more inclusive definition, including patients who received immunotherapy against antibody 
production but did not meet the 2011 ISHLT criteria.
4
 Everitt et al. reported pAMR2 or higher occurring 
in 59% of patients and 18% of biopsies, including 12% of patients experiencing pAMR3, however their 
study examined an earlier patient cohort over a longer follow-up period.
11
 Using an updated cohort of 
pediatric HT patients followed between 2009-2013, Ware et al. reported pAMR occurring in 21% of 
patients and 11% of biopsies.
12
 Our finding that pAMR2 occurred in 7% of patients was similar to that of 
Clerkin et al., who using the 2013 ISHLT pAMR criteria, reported a 10% incidence of AMR over >10 years 





We found the presence of preformed IgG+ DSA at transplant to be associated with pAMR development, 
as has been reported by others; however, we also observed that 86% patients who developed pAMR2 
had new C1q+ DSA at the time of diagnosis, supporting the hypothesis that complement fixation plays 
an important role in the pathology of pAMR,.
12, 14, 18-20
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this study is the result of our institutional policy to ensure a C1q-DSA negative virtual crossmatch at the 
time of donor acceptance, though further study is warranted.  
 
 
Because of the overall low incidence of pAMR2 in our study, clinical risk factors for pAMR2 development 
were difficult to establish in this series. Nevertheless, we found that a history of CHD and not having a 
history of VAD support were more common in patients who developed pAMR2. CHD history has been 
established previously as a risk factor for AMR, likely due to increased HLA sensitization from exposure 
to blood transfusions and/or homograft tissue.
4, 21
 Conversely, whereas a history of VAD support has 




 Our finding that VAD-supported patients were less likely to develop pAMR2 is most probably 
related to the disproportionate use of VADs in children with cardiomyopathy versus those with CHD 
rather than to any protective effect from VAD use. 
The present study also found that early pAMR2 development trended towards reduced survival and was 
associated with higher filling pressures, though it is important to note that pAMR diagnosis was not 
associated with an acute change in filling pressures. It is also important to acknowledge that the overall 
incidence of pAMR in this study was very low, limiting the study’s ability to draw conclusions as to the 
effect of pAMR diagnosis on survival. It is quite possible that the trend towards reduced survival in those 
with a history of pAMR2 observed in this study was the result of coincident factors present in patients 
with higher risk for pAMR development (e.g. sensitization, congenital heart disease, etc.). Nevertheless, 
the findings of this study are consistent with those of Clerkin et al., who reported decreased post-AMR 




 Given the infrequency of pAMR (<1% of biopsies), however, a targeted approach to 
surveillance in patients at risk for pAMR may be prudent. 
Despite a lack of guidelines or even a strong consensus about what constitutes best practice, it has been 
our institutional approach to treat pAMR2, even in the absence of altered hemodynamics or 
concomitant ACR. In the present study, all but 1 pAMR2 episode was treated with either IVIG alone, a 
combination of IVIG and plamsmapheresis, or, in 1 case, IVIG/plasmapheresis/rituximab/bortezomib. 
The use of IVIG +/- plasmapheresis and/or rituximab is consistent with practices reported by other 
centers, with evidence supporting the use of bortezomib limited to smaller series.
4, 25, 26
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note, however, that in the present study all episodes of pAMR2 resolved, including one episode that was 
not treated, but that resolution of pAMR did not appear to abrogate mortality risk. Although the 
relationship between AMR and increased risk for poor outcomes even after treatment is well-
established, our finding that a single acute pAMR2 episode may herald graft loss, perhaps due to chronic 
diastolic dysfunction and/or accelerated CAV development, highlights the importance of a pAMR 
prevention strategy at the time of transplantation. 
4, 8, 9, 11, 17
 
   
This study is limited by its retrospective nature and the potential for error inherent upon chart review, 
as well as a lack of standardization of immunosuppressive regimens over time and individual variability 
in immunomodulatory therapies. Furthermore, our quantitative interpretation of antibody strength was 
assumed by MFI, which due to the possibility of the prozone effect and other factors is not a true 
surrogate for antibody titer.  It is also limited by our inability to distinguish pAMR1i from pAMR0. 
Because immunohistochemical staining is not performed universally on all biopsies, the true incidence 
of pAMR1i could not be ascertained and the outcomes following pAMR1i could not be determined. It is 
also important to note that the false positive rate for pAMR may be higher in the first two postoperative 
weeks when the majority of cases were detected.
6
 Moreover, variations in center practice with regard to 
routine EMB screening limit the generalizability of the results of this single center study.
27
 
 Because the 
majority of pAMR episodes in this study were detected during routine screening, centers that perform 
fewer EMBs in asymptomatic patients may find a lower incidence of pAMR as a result of missed events. 
Lastly, because of the low incidence of pAMR, our ability to identify risk factors for pAMR development 
was limited. Nevertheless, this study adds valuable information to the current understanding of pAMR 
using standardized definitions, long-term follow-up, robust DSA data, frequent hemodynamic 
surveillance, and relatively large sample size.  
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White 
 
44 (46%) 5 (71%) 39 (44%) 0.16 
African American 
 
6 (6%) 1 (14%) 5 (6%)  
Hispanic/Latino 
 




8 (8%) 0 (0%) 8 (9%)  
Other 
 
3 (3%) 0 (0%0 3 (3%)  
Pre-Transplant Diagnosis 
 
   0.02* 
Cardiomyopathy 
 
54 (56%) 1 (14%) 53 (60%)  
CHD 
 
40 (42%) 6 (86%) 34 (38%)  




























Duration of Follow-Up (Years) 
 
3.1 (1.9, 4.6) 
 
4.7 (1.4, 5.2) 
 
3 (1.9, 4.5) 
 
0.56 
     
 
Data presented as Median (quartile 1 – quartile 3) or count (% of column)  
*Retransplants not included in this analysis. 
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12 (+/- 6) 
 




Mean PCWP,  
n=1325 
 



















Mean RA pressure/PCWP ratio, 
n=1314 
 
2 (+/- 1) 2 (+/- 0.5) 2 (+/- 1) 0.20 
 
Data are normally distributed and are presented as mean (+/- standard deviation) 
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A2, A24 5 N/A N/A AMR 
resolved, 
alive 
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